<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: FDA Wants Your Comments on 180-Day Exclusivity Forfeiture</title>
	<atom:link href="http://www.patentbaristas.com/archives/2007/09/28/fda-wants-your-comments-on-180-day-exclusivity-forfeiture/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.patentbaristas.com/archives/2007/09/28/fda-wants-your-comments-on-180-day-exclusivity-forfeiture/</link>
	<description>Freshly Brewed Bio/Pharma Chat. Served Up Daily.</description>
	<lastBuildDate>Thu, 18 Mar 2010 11:54:35 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: MMA News &#187; FDA Wants Your Comments on 180-Day Exclusivity Forfeiture</title>
		<link>http://www.patentbaristas.com/archives/2007/09/28/fda-wants-your-comments-on-180-day-exclusivity-forfeiture/comment-page-1/#comment-24392</link>
		<dc:creator>MMA News &#187; FDA Wants Your Comments on 180-Day Exclusivity Forfeiture</dc:creator>
		<pubDate>Fri, 28 Sep 2007 21:42:51 +0000</pubDate>
		<guid isPermaLink="false">http://www.patentbaristas.com/archives/2007/09/28/fda-wants-your-comments-on-180-day-exclusivity-forfeiture/#comment-24392</guid>
		<description>[...] This Week&#8217;s Sports &amp; Recreation News wrote an interesting post today onHere&#8217;s a quick excerptThe FDA’s Office of Generic Drugs posted a letter requesting comment on certain 180-day exclusivity forfeiture and Orange Book patent “delisting” issues.  This concerns an ANDA submitted to the FDA containing a paragraph IV patent certification&#8230; [...]</description>
		<content:encoded><![CDATA[<p>[...] This Week&#8217;s Sports &amp; Recreation News wrote an interesting post today onHere&#8217;s a quick excerptThe FDA’s Office of Generic Drugs posted a letter requesting comment on certain 180-day exclusivity forfeiture and Orange Book patent “delisting” issues.  This concerns an ANDA submitted to the FDA containing a paragraph IV patent certification&#8230; [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
